生物活性：Carbamazepine-d8 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent, with an IC50 of 131 μM[1][2].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Carbamazepine-d8 相关抗体:
xCT Antibody (YA006)
xCT Antibody (YA652)
Alpha-ENaC Antibody
CRMP2 Antibody (YA3370)
SLC12A1 Antibody (YA1403)
CRMP1 Antibody (YA1941)
CRMP5 Antibody (YA2497)
CRMP3 Antibody (YA2563)
CRMP4 Antibody (YA2777)
分子量：244.32
Formula：C15H4D8N2O
CAS 号：1538624-35-9
非标记 CAS：298-46-4
性状：固体
颜色：Off-white to light yellow
中文名称：卡马西平-d8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years
In solvent：-80°C：6 months，-20°C：1 month
纯度 & 产品资料
纯度： 98.70%
参考文献
[1]. Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35.
 [Content Brief]
[2]. Okada, M., et al., Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res, 1997. 28(2): p. 143-53.
 [Content Brief]
[3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]